US EditionPublished • loading... • Updated
GLP-1 Discontinuation Associated with More Weight Gain and Pregnancy Complications
Stopping GLP-1 receptor agonists before or early in pregnancy led to an average 7.1 lb greater gestational weight gain and increased risks of gestational diabetes and preterm delivery.
- On November 24, 2025, Mass General Brigham published findings led by Jacqueline Maya, MD, in JAMA Network Open on GLP-1 receptor agonists and pregnancy risks.
- Because GLP-1 agents are contraindicated in pregnancy due to animal toxicity studies reporting fetal abnormalities, many women of reproductive age stop GLP-1 receptor agonists before conception.
- In a matched cohort of 1,792 pregnancies, women who stopped GLP-1 agents had 7.1 lb greater gestational weight gain and 29%-34% higher risks of diabetes, hypertension, and preterm delivery.
- Authors warned clinicians managing reproductive-age patients on GLP-1s to monitor risks of gestational weight gain and complications, as `more research is needed to determine the best approach`, Maya said.
- Study limitations and guidance gaps mean authors call for more research, noting the retrospective study design, semaglutide labeling advising stopping at least two months before planned pregnancy, and limited preconception guidance.
Insights by Ground AI
25 Articles
25 Articles
Coverage Details
Total News Sources25
Leaning Left2Leaning Right0Center7Last UpdatedBias Distribution78% Center
Bias Distribution
- 78% of the sources are Center
78% Center
L 22%
C 78%
Factuality
To view factuality data please Upgrade to Premium
